Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Genfit (GNFTp)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
3.26 +0.00    +0.00%
03/04 - Delayed Data. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Euro Zone
ISIN:  FR0004163111 
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 3.26 - 3.26
Genfit 3.26 +0.00 +0.00%

Genfit SA Company Profile

 
Get an in-depth profile of Genfit, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

154

Equity Type

ORD

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Contact Information

Address Parc EurasantE 885, avenue EugEne AvinEe
Loos, 59120
France
Phone 33 3 20 16 40 00
Fax 33 2 20 16 40 01
Web www.genfit.com

Top Executives

Name Age Since Title
Xavier Guille des Buttes 79 2006 Independent Vice-Chairman of the Board
Jean-Francois Mouney 66 1999 Co-Founder & Chairman of the Board
Bart Staels 58 - Co-Founder & Chairman of the Scientific Advisory Board
Catherine Larue 66 2011 Independent Director
Florence Séjourné 51 1999 Director
Philippe Moons 71 2015 Board Observer
Anne-Helene Monsellato 54 2017 Independent Director
Scott L. Friedman - - Member of Scientific Advisory Board
Eric Baclet 63 2020 Independent Director
Michael Trauner - - Member of Scientific Advisory Board
Jean-Francois Tine 66 2021 Independent Director
Katherine Bach Kalin 60 2020 Independent Director
Vlad Ratziu - - Member of Scientific Advisory Board
Sandra Silvestri - 2023 Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

GNFT Comments

Write your thoughts about Genfit SA
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Moms Naim
Moms Naim Jan 02, 2024 6:56AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
GENFIT : ENFIN COMMERCIALISÉE EN 2024, LA BIOTECH GENFIT
Reply
1 0
Report
Aynaz Rostami
Aynaz Rostami Feb 11, 2021 9:57AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
what's the reason of fall of Genfit?
Reply
0 0
Report
ziqing liew
ziqing liew Feb 11, 2021 9:57AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
i also want to know
Reply
1 0
Report
Aynaz Rostami
Aynaz Rostami Feb 11, 2021 9:57AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
dont worry it Will raise soon
Reply
0 1
Report
Thao Bui
Thao Bui Jun 26, 2020 4:57AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
it cheap to buy
Reply
0 0
Report
CAC Invest
CAC Invest Jun 09, 2020 5:39AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Trials for NASH will continue after dataset correction
Reply
0 2
Report
Thms Koprnk
Koprnk Jun 04, 2020 6:57AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
they failed the drug test and NASH drug was the only viable drug that they were developing , so practically they lost almost all value with that failure...
Reply
1 1
Report
CAC Invest
CAC Invest Jun 04, 2020 6:57AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
not all value but a drug development. they have so many programs to continue
Reply
1 0
Report
Danny Danny
Danny Danny May 21, 2020 1:03PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
damn what was wrong w this beast? from 2x all the way down to 5 w low volume?
Reply
1 0
Report
Rajaie Issaid
Rajaie Issaid May 20, 2020 4:15PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Whats the status , will it still go down ?
Reply
0 0
Report
Malek Brahmi
Malek Brahmi May 20, 2020 4:15PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Yes
Reply
0 0
Report
stats con chris
stats con chris May 19, 2020 2:27PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
this baby Is the brother of contravirpharma (HEPA) .. same diseases.
Reply
0 0
Report
MfB Iod
MfB Iod May 19, 2020 2:27PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
what do you mean?
Reply
0 0
Report
Nedal Aysheh
Nedal Aysheh May 12, 2020 5:53PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
WHAT IS THE BEST STOCK TO BUY TODAY ??/ ANT RECOMMENDATION
Reply
1 0
Report
MfB Iod
MfB Iod Mar 27, 2019 12:56PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
does anyone have an explaination for the sudden fall same day of the Nasdaq trading?
Reply
1 0
Report
Show previous replies (5)
Mathieu Gandrille
Mathieu Gandrille Mar 27, 2019 12:56PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
MfB Iod  possible. today it will open low, in a range between 5 to 8. (my guess only - dyor)
Reply
0 0
Report
Mathieu Gandrille
Mathieu Gandrille Mar 27, 2019 12:56PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
MfB Iod   i changed my recommendation to SELL, with objective at 8.0
Reply
0 0
Report
MfB Iod
MfB Iod Mar 27, 2019 12:56PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Mathieu Gandrille  ah you mean to buy because it would be oversold
Reply
0 0
Report
Mathieu Gandrille
Mathieu Gandrille Mar 27, 2019 12:56PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
MfB Iod   i mean if 5 i would buy, and sell at 8
Reply
0 0
Report
Olivier Bclr
Olivier Bclr Mar 27, 2019 12:56PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Mathieu Gandrille  are you a KOL?
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email